Результаты поиска

Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.

BACKGROUND: Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous system. The treatment of MS has always be … izumab, 0.51 (0.43, 0.61); fingolimod, 0.57 (0.50, 0.65); peginterferon beta-1a, 0.63 (0.52, 0.77); dimethyl fumarate, 0.65 (0.56, 0.74); teriflunomide 14 mg, 0.78 (0.66, 0.92); glatiramer acetate, 0.80 (0.72, 0.89); IFN β-1a (Rebif), 0.81 (0.72, 0.90); IFN β-1b (Betaseron), 0.81 (0.72, 0.91); teriflunomide 7 mg, 0.83 (0.71, 0.98); and IFN β-1a (Avonex). 0.87 (0.77 …

Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis.

BACKGROUND: The approval of new oral disease-modifying drugs (DMDs), such as fingolimod, dimethyl fumarate (DMF), and teriflunamide, has considerably expanded treatment options for relapsing forms of multiple sclerosis (MS). However, data describing the use of these agents in routine clinical practice are limited. OBJECTIVE: To describe time trends and identify factors associated with oral DMD treatment initiation and switching among individuals with MS. METHODS: Using data from a large sample of commercially insured patients, we evaluated changes over time in the proportion of MS patients w…

Dimethylfumarate effectively inhibits lymphangiogenesis via p21 induction and G1 cell cycle arrest.

Different pathologies, such as lymphoedema, cancer or psoriasis, are associated with abnormal lymphatic vessel formation. Therefore, influencing lymphangiogenesis is an interesting target. Recent evidence suggests that dimethylfumarate (DMF), an antipsoriatic agent, might have antitumorigenic and antilymphangiogenic properties. To prove this assumption, we performed proliferation and functional assays with primary human dermal lymphendothelial cells (DLEC). We could demonstrated that DMF suppresses DLEC proliferation and formation of capillary-like structures. Underlying apoptotic mechanisms c

Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.

Pediatric-onset multiple sclerosis (POMS) is a rare neuroinflammatory and neurodegenerative disease that has a significant impact on long-te … nts. An increasing number of POMS patients are now treated with moderate efficacy therapies such as dimethyl fumarate and high-efficacy therapies such as natalizumab, anti-CD20 monoclonal antibodies, anti-CD52 monoclonal antibodies, and/or autologous hematopoietic stem cell transplantation. These high-efficacy DMTs generally provide additional reduction in inflamma …

Current and future trends in multiple sclerosis management: Near East perspective.

BACKGROUND: Multiple sclerosis (MS) prevalence is rising in the Middle East. Most MS medications are available in the region, but not all, p … feron beta 1a SC, Fingolimod, and Glatiramer acetate were the most commonly recommended treatments. Dimethyl fumarate substituted fingolimod in female patients. Interferon beta 1a SC was the safest treatment for mild to moderate RRMS. Interferon beta 1a SC was preferred over other treatments for patients with mild to moderate MS and planning for pregnancy (56.6%) o …

The importance of physiotherapy in the sexuality of patients with rheumatic diseases.

OBJECTIVE: Dimethyl fumarate (DMF) has shown anti-inflammatory and antioxidant activities. However, the effects of DMF on gouty arthritis remain elusive, and the underlying mechanism is not understood. In this study, we aim to investigate the role of DMF in gouty arthritis. MATERIALS AND METHODS: Mice were gavage with DMF for consecutive 7 days at two different doses (10 mg/kg/day or 30 mg/kg/day, once daily) in advance and then monosodium sodium urate (MSU) was injected into their joint to establish an acute gout mice model. The pain and swelling of the hind paw in mice were determined. The …

Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020.

IMPORTANCE: Many disease-modifying therapies (DMTs) have been approved for multiple sclerosis (MS) in the past 2 decades. Research evaluatin … ldren showed similar initiation patterns, except for preferred oral therapy. Between 2019 and 2020, dimethyl fumarate was the most commonly initiated DMT in adults (23.3% to 27.2% of all initiations), while in children fingolimod was the most commonly initiated (34.8% to 68.8%). CONCLUSIONS AND RELEVANCE: Current MS treatment guidelines emphasize shared decision-m …

Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.

BACKGROUND AND OBJECTIVES: Uncontrolled evidence suggests that autologous hematopoietic stem cell transplantation (AHSCT) can be effective i … amer-acetate, mitoxantrone, fingolimod, natalizumab, methotrexate, teriflunomide, cyclophosphamide, dimethyl fumarate, and alemtuzumab) were matched to reduce treatment selection bias using propensity score and overlap weighting approaches. Time to first CDP was significantly longer in transplanted patients (hazard ratio [HR] = 0.50; 95% CI = 0.31-0.81; p = 0.005), …

Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database.

Given the importance of inflammation at the onset of multiple sclerosis (MS), therapy is mainly based on the use of anti-inflammatory drugs … (PEG-IFN β-1a), glatiramer acetate (GA), natalizumab (NTZ), fingolimod (FNG), teriflunomide (TRF), dimethyl fumarate (DMF), alemtuzumab (Alem), ocrelizumab (OCZ), or cladribine (Cladr), were collected. Descriptive analyses of national, publicly-available aggregated data and full-access regional data were performed to assess demographic characteristics and drug-rel …

Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.

BACKGROUND: Safety and effectiveness outcomes in Multiple Sclerosis (MS) patients receiving different disease-modifying therapies (DMT) and different types of vaccines against SARS-CoV-2 are limited. Growing evidence coming mainly from Israel, Europe and North America using mRNA and adenoviral vector vaccines has been published. OBJECTIVES: To assess the safety and humoral response of inactivated virus and mRNA vaccines against SARS-CoV-2 in patients with MS. METHODS: Ongoing, multicentric, prospective, observational study performed between February and September 2021. Humoral response (anti

Иммуномодуляторы и иммунопрессанты для релапсирующего многократного склероза: сетевой метаанализ.

ЦЕЛЬ: Существуют различные терапевтические стратегии для лечения лиц с повторно излучающимся множественным склерозом (РРМС), включая иммуномодуляторы, иммунодепрессанты и биологические агенты. Хотя и каждый one Из этих методов снижается частота рецидивов и замедляется накопление инвалидности по сравнению с отсутствием лечения, и их относительные преимущества остаются неясными. Это обновленный вариант обзора Кокрана, опубликованного 2015.ЦЕЛИ: Сопоставление эффективности и безопасности интерферона с помощью сетевого метаанализа beta-1bИнтерферон beta-1a, глатирамерный ацетат, натализумб, митокс

Совпадение в аннотации оригинала
BACKGROUND: Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple sclerosis (RRMS), i … a-1b, interferon beta-1a, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, pegylated interferon beta-1a, daclizumab, laquinimod, azathioprine, immunoglobulins, cladribine, cyclophosphamide, diroximel fumarate, fludarabine, interferon beta 1-a and beta 1-b, leflunomide, methotrexate, minocycline, mycophenolate …

Bufei Yishen formula ameliorates chronic obstructive pulmonary disease by restoring alveolar macrophage efferocytosis through Nrf2 activation.

ETHNOPHARMACOLOGICAL RELEVANCE: Bufei Yishen formula (BYF) is a traditional Chinese medicine (TCM) prescription clinically used to improve p … flammation, efferocytosis, oxidative stress, and Nrf2 signaling. Nrf2 involvement was verified with dimethyl fumarate and ML385, and Nrf2-binding constituents of BYF were identified using Affinity ultrafiltration-LC/MS (AU-LC/MS), molecular docking, and surface plasmon resonance (SPR). RESULTS: scRNA-seq analysis revealed that impaired macrophage efferocytosis is …

Lycorine suppresses DPP3-mediated Nrf2 signaling, thereby reducing SLC7A11 levels to trigger ferroptosis in colorectal cancer cells.

BACKGROUND: Colorectal cancer (CRC) exhibits high morbidity/mortality with poor late-stage survival, creating an urgent need for effective t … and cells were treated with lycorine, nuclear factor erythroid 2-related factor 2 (Nrf2) activator dimethyl fumarate (DMF), or Nrf2 inhibitor Nrf2 inhibitor (ML385), followed by detection of cell proliferation, apoptosis, invasion, reactive oxygen species (ROS), intracellular Fe²⁺ level, GSH/GSSG ratio, Malondialdehyde (MDA)level, 4-Hydroxynonenal (4-HNE) level an …

Cerebral tumefactive demyelinating lesions: clinical spectrum, long-term outcomes, and treatment.

BACKGROUND: Tumefactive demyelinating lesions (TDLs) are tumor-like inflammatory demyelinating lesions that may occur within the spectrum of … (48.8%) patients, whereas platform therapies (interferon β-1a, interferon β-1b, glatiramer acetate, dimethyl fumarate, teriflunomide) were used in 11 (26.8%) patients. Four (9.8%) patients received no disease-modifying treatment. CONCLUSION: Our findings demonstrate that TDLs represent a radiological phenotype associated within a spectrum of neuroinflammatory diso …

Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides.

BACKGROUND AND OBJECTIVES: Epstein-Barr virus (EBV) has been strongly implicated in the pathogenesis of multiple sclerosis (MS). Despite thi … disease-modifying treatments (DMTs) including natalizumab, anti-CD20 monoclonal antibodies (mAbs), dimethyl fumarate (DMF), and also treatment naïve. Whole blood samples were stimulated with commercially available PepTivator EBNA1 peptides and a control virus-cytomegalovirus (CMV) peptide. We recorded the cellular response to stimulation with both interferon gamma …

Validation of the multiple sensor mechanism of the Keap1-Nrf2 system.

The Keap1-Nrf2 system plays a critical role in cellular defense against electrophiles and reactive oxygen species. Keap1 possesses a number of cysteine residues, some of which are highly reactive and serves as sensors for these insults. Indeed, point mutation of Cys151 abrogates the response to certain electrophiles. However, this mutation does not affect the other set of electrophiles, suggesting that multiple sensor systems reside within the cysteine residues of Keap1. The precise contribution of each reactive cysteine to the sensor function of Keap1 remains to be clarified. To elucidate the

Dimethylfumarate inhibits melanoma cell proliferation via p21 and p53 induction and bcl-2 and cyclin B1 downregulation.

Recent evidence suggests that dimethylfumarate (DMF), known as a highly potent anti-psoriatic agent, might have anti-tumorigenic properties in melanoma. It has recently been demonstrated that DMF inhibits melanoma proliferation by apoptosis and cell cycle inhibition and therefore inhibits melanoma metastasis. Nonetheless, the underlying mechanisms remain to be evaluated. To elucidate the effects of DMF on melanoma cell lines (A375, SK-Mel), we first performed cytotoxicity assays. No significant lactatedehydogenase (LDH) release could be found. In further analysis, we showed that DMF suppresses

Потенциал нейрозащиты Герберы Джеймсони в нейрональной модели обезвоживания крыс посредством модуляции интерлейкинов, циклоксигеназы и некроза опухоли-α.

Множественный склероз характеризуется обезвоживанием нейронов, которое является хроническим воспалительным заболеванием центральной нервной системы. Это аутоиммунное расстройство происходит из-за дисбаланса в иммунной системе организма в результате неконтролируемого окислительного стресса. Б и Т лимфоциты пересекают кровеносный барьер и уничтожают милиновую оболочку. Множественный склероз является одной из наиболее распространенных причин инвалидности среди молодых людей, затрагивающих примерно 3 миллиона человек во всем мире. Среди них женщины относятся к группе повышенного риска по сравнению

Совпадение в аннотации оригинала
Multiple sclerosis is characterized by the demyelination of neurons, which is a chronic inflammatory disease of the central nervous system. … e randomly divided into seven groups (n = 10): normal, demyelination disease model, standard drugs, dimethyl fumarate and fingolimod (FTY 720) 15 mg/kg, and three treatment groups: GJ-NPs 250 mg/kg, 500 mg/kg, and 750 mg/kg. Prior to treatment, 0.2% cuprizone solution was prepared for the induction of multiple sclerosis in all groups except the normal group for 42 …

Untackling the economics of multiple sclerosis: A systematic review of economic evaluations of disease-modifying therapies indicated for multiple sclerosis

OBJECTIVES: Multiple sclerosis (MS) comprises a chronic, neurodegenerative, and inflammatory illness of the central nervous system that affe … d timeframe of the trial and time horizon of the model exerted a substantial impact on the results. Dimethyl fumarate was consistently interrelated with a positive cost-effectiveness ratio. The same applies for fampridine, while Cladribine was proved to be a dominating agent. Ocrelizumab also evinced efficiency. The same applies for the early data of Siponimod and …